Study suggests adjusting PSA scores for obese men or cancers may be missed

Doctors may be missing cancers in obese men because the telltale blood marker used to detect the disease can be falsely interpreted as low in this population, according to a new study led by Duke Prostate Center researchers.

“Obese men have more blood circulating throughout their bodies than normal weight men, and as a result, the concentration of prostate-specific antigen, or PSA, in the blood -- the gold standard for detecting prostate cancer -- can become diluted,” said Stephen Freedland, M.D., a Duke urologist and senior researcher on a study appearing in the November 21, 2007 issue of the Journal of the American Medical Association.

“We’ve known for a while that obese men tend to have lower PSA scores than normal weight men, but our study really proposes a reason why this happens, and points to the need for an adjustment in the way we interpret PSA scores that will take body weight into account. If not, we may be missing a large number of cancers each year.”

The study was funded by the Department of Veterans Affairs, the Duke Department of Surgery and Division of Urology, the Department of Defense Prostate Cancer Research Program, the American Urological Association Foundation, the Georgia Cancer Coalition, and the National Institutes of Health.

Researchers compared the medical records of almost 14,000 patients who had undergone radical prostatectomy surgery for the treatment of prostate cancer between 1988 and 2006 at Johns Hopkins, Duke, or at one of five Veterans Affairs hospitals making up the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. They analyzed the relationship between body mass index -- which is a measure of obesity -- and PSA concentration levels, while also examining the blood volume in the patients’ bodies and the total amount of PSA protein found in the blood, known as PSA mass, Freedland said.

“We found that a higher body mass index directly correlated with higher blood volume and lower PSA concentrations,” said Lionel Bañez, M.D., a prostate cancer researcher in the Duke Prostate Center and lead author on the publication. “Men in the most obese group had PSA concentrations that were 11 to 21 percent lower than those of normal weight men.”

In this study, PSA mass across all groups was comparable despite differences in body weight, leading the researchers to believe that the larger blood volume is responsible for lowering the concentration of PSA, which is what doctors typically measure when looking for prostate cancer, Freedland said.

“It’s as if you dissolve a tablet in a cup of water versus a tub of water,” he said. “The concentration of the drug in the cup will be much higher than that in the tub, even though the amount is the same.”

These findings are very important because of the sheer number of people they affect, Freedland said.

“One in three Americans is obese, and it’s not just the very large people that you think of who fall into this category,” he said. A man who is 5’11” and weighs 215 pounds is considered obese.

"Our study shows yet another potentially serious consequence of this country's growing epidemic of obesity," said Carmen Rodriguez, MD, an American Cancer Society epidemiologist and co-author of the study. "Previous studies have linked obesity to more aggressive prostate cancers. Our finding that prostate cancer may also be more difficult to detect in this population generates a dangerous 'one-two punch' for men who are overweight or obese."

If their prostate cancers are being detected later because of the dilution of PSA, this may help, in part, to explain why obese men tend to have more aggressive cancers, Freedland said.

Source: Duke University Medical Center

Related stories:

New catheter-less technique may ease the pain and discomfort of prostate cancer recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.
Study: When/if to start hormones for prostate cancer patients whose PSA rises after radiation
A new Fox Chase Cancer Center study suggests men with early stage prostate cancer treated with radiation therapy should begin hormone therapy immediately if their PSA level rises quickly and doubles within six months at any time after treatment. The study also supports foregoing hormones if the PSA doesn't rise as quickly. Both findings suggest a change in the practice of prescribing hormones is warranted.
Common painkillers lower levels of prostate cancer biomarker
Common painkillers like aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer.
Health risk behaviors associated with lower prostate specific antigen awareness
According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening. Although previous studies have explored predictors of PSA test awareness, this is the first research to focus on health risk behaviors, such as smoking, physical inactivity, obesity, and excessive alcohol consumption. The study findings were reported in the August issue of The Journal of Urology.
Hair on a man's head offers clues about prostate cancer
Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.
Prostatectomy improves outcome of some men with prostate cancer over watchful waiting
Men with early prostate cancer who undergo radical prostatectomy have a lower rate of death due to prostate cancer than men who are followed without treatment, known as watchful waiting, according to a randomized controlled trial published in the August 12 online issue of the Journal of the National Cancer Institute. The benefit from the surgery, with respect to prostate cancer death rates, remained constant beyond 10 years, but the overall death rates in the two groups were not statistically different. The applicability of the results to the current generation of prostate cancer patients is unclear, however, because few of the cancers treated in the trial were discovered by PSA (prostate-specific antigen) screening, a practice that is now widespread.
Study finds more PSA screening awareness needed among high-risk groups
In one of the first examinations of PSA screening in younger men, a study published by researchers at Duke Medicine's Prostate Center finds that one-fifth of men under age 50 reported undergoing a prostate specific antigen (PSA) test to detect prostate cancer in the previous year, yet only one in three young black men reported ever having a PSA test in the previous year.
1 in 5 young men has had recent prostate cancer test
A new analysis finds that one in five men in their 40s has had a prostate specific antigen (PSA) test within the previous year and that young black men are more likely than young white men to have undergone the test. The study, published in the September 15, 2008 issue of Cancer, a peer-reviewed journal of the American Cancer Society, provides valuable information as experts discuss possible changes to prostate cancer screening recommendations.

News discussion:

Medicine & Health news